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Hepatitis E virus (HEV) infection is likely an old disease that
has been affecting humans for centuries but has only been recog-
nized in the second half of the 20th century. The ﬁrst clinical
description of HEV came after an outbreak in New-Delhi in
1955 [1]. This was followed by its clinical, morphologic, serologic,
and molecular characterization between 1980 and 2009 [2–7].
Transmission of HEV infection and its epidemiology are similar
but not identical to hepatitis A virus infection. HEV outbreaks
occur through fecal-oral transmission and are mainly waterborne
but may also occur through person to person contact and rarely
through blood transfusion. Following the development of
improved serologic and molecular diagnostic tools, the detection
of autochthonous cases in non-endemic countries in the Western
hemisphere and the development of several efﬁcacious recombi-
nant vaccines, HEV is gaining renewed global attention. Thus,
Hepatitis E became the focus of two recent meetings of the Viral
Hepatitis Prevention Board-VHPB in 2009 in Belgium (http://
www.vhpb.org/hepatitis A and E: update on prevention and epi-
demiology) and the International Vaccine Institute-IVI in 2010 in
Korea (http://www.ivi.int/main.asp). The true global burden of
HEV disease (GBD) is not known and a number of international
organizations are now collaborating and in the process of devel-
oping a model for an assessment of the GBD. A World Health
Organization (WHO) estimate, based on selected seroprevalence
data and case series suggests that at least one third of the world
population, residing mainly in Asia, Africa, Middle East, and Cen-
tral America has already been infected (WHO Viral Hepatitis
Statement A62/22. http://apps.who.int/gb/ebwha/pdf). While
acute hepatitis E is common in endemic countries where it is
notoriously associated with a high mortality rate in pregnant
women, it has recently been recognized that anti-HEV(IgG) anti-
bodies may be detectable in 3–21% of distinct populations in the
industrialized countries who had no history of clinically apparent
hepatitis or travel to endemic regions. Sequencing of HEV-RNA
revealed the presence of 4 major genotypes. Genotype 1and 2
infect only humans while genotypes 3 and 4 have been isolated
from humans as well as from domestic pigs, wild boars, deer
and other animals, mainly in industrialized countries. Genotype
3 and 4 are nowadays considered as zoonotic infections thatJournal of Hepatology 20
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genotypes 1 and 2, prevalent in endemic regions, mainly in Asia
and Africa [8]. The relatively high seroprevalence of anti-
HEV(IgG) antibodies in the Western hemisphere has been linked
to clinically occult infection following the consumption of
uncooked meat of infected animals although person to person
contact has also been reported. It is not yet known whether sero-
conversion to anti-HEV(IgG) persists indeﬁnitely providing long-
term immunity against a re-challenge with HEV.
In the present issue of the journal, Romano and co-workers
[9] report the results of a serologic and molecular phylogenetic
analysis in Italian patients with acute hepatitis E. The diagnosis
of acute hepatitis E was established via serologic assays for anti-
HEV (IgM) in 134/651 patients with non-A, B, C acute hepatitis
of whom 72% had evidence for HEV viremia by HEV-RNA
PCR. HEV was also identiﬁed in stool specimens of some individ-
uals. All patients with acute HEV infection tested positive for
anti-HAV (IgM) as well as anti-HEV (IgG). Interestingly, 6% of
the entire 517 cohort of acute non-A, B, C, and E hepatitis tested
positive for anti-HEV (IgG) but negative for anti-HEV (IgM) and
undetectable HEV-RNA. These results may suggest past exposure
to HEV in these non-A–E patients with acute hepatitis or rapid
clearance of HEV following acute infection. This 6% seropreva-
lence rate may be an underestimation in view of the changing
speciﬁcity of the four different commercial and one in-house
anti-HAV assays used by the investigators along the study
period.
Not surprisingly, 81% of patients with proven HEV infection
had a history of international travel to HEV endemic countries.
The molecular analysis of 39 isolates obtained from such travel-
ers revealed the presence of genotype 1. In contrast 22/134
patients (20.6%) with acute hepatitis E diagnosed between 1994
and 2009, had no history of travel to endemic countries. HEV,
genotype 3, which has previously been identiﬁed in pigs, and
wild boars in Italy and elsewhere was identiﬁed in ﬁve isolates
from these 22 patients who did not have any known risk factor
for HEV infection. Assuming that this result, obtained in 5/22
non-traveler patients is representative, it seems that genotype
3 is the dominant genotype responsible for sporadic HEV infec-
tions in Italy.
This extensive survey contributes additional information to
our knowledge of the epidemiology of HEV infection in industri-
alized countries in general and in Italy in particular. The study
also conﬁrms a number of previous observations regarding the
role of HEV genotype 3 and possible exposure to contaminated
food in the epidemiology of HEV in Europe. Excluding pregnant11 vol. 54 j 1–2
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women, acute HEV infection is a self-limited disease which may
cause signiﬁcant morbidity but that usually has a favorable
outcome. It does not lead to chronic hepatitis except in immune
suppressed patients i.e. after organ transplantation [10]. It is dif-
ﬁcult to explain why 3–20% of distinct populations in industrial-
ized countries such as the US, various European regions
including Italy, Australia, and elsewhere have evidence for past
HEV infection as determined by positive anti-HEV (IgG) and
undetectable HEV-RNA or anti-HAV (IgM). Genotype 3 associ-
ated acute hepatitis E seems clinically less virulent as compared
to genotype 1 and 2. One hypothesis suggests that taking into
account this difference in the clinical manifestations, genotype
3 HEV has been attenuated through passage in zoonotic hosts
and as a result the infection in humans is sub-clinical and
asymptomatic. The identiﬁcation of such genotype 3 isolates
and the relatively low burden of clinical disease in non-travelers
are expected to have at present a limited public health impact in
the industrial countries. Hepatitis E is a vaccine-preventable dis-
ease and poses a real hazard to pregnant women in Asia and
Africa but signiﬁcantly less so in Western countries. Interna-
tional travelers are at risk for HEV infection when traveling to
endemic areas as also shown in the study from Italy. However,
the introduction of new HEV vaccine(s) into clinical practice
awaits further assessment of the GBD, prioritization of interven-
tion and allocation of resources. Meanwhile, it is desirable to
educate the public regarding the importance of avoiding the
consumption of raw meat and uncooked sausages especially in
industrialized countries.Conﬂict of interest
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